Matrix metalloproteinase inhibitors

Investigational New Drugs

Volumn 15, Issue 1, 1997, Pages 61-75

  Wojtowicz Praga, Slawomir M ^a,b   Dickson, Robert B ^a   Hawkins, Michael J ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b Theradex   (United States)

Author keywords

Angiogenesis; Clinical trials; Human malignancies; Matrix metalloproteinase inhibitors

Indexed keywords

BATIMASTAT; BRYOSTATIN; COLLAGEN; FIBRONECTIN; LAMININ; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE PROTEIN; PROTEIN KINASE C; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BASEMENT MEMBRANE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL GROWTH; CHEMICAL STRUCTURE; DRUG SOLUBILITY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GROWTH INHIBITION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DOWN-REGULATION; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; HYDROXAMIC ACIDS; METALLOENDOPEPTIDASES; MOLECULAR WEIGHT; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHENYLALANINE; PROTEASE INHIBITORS; PROTEIN KINASE C; PROTEINS; THIOPHENES; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0030929371     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005722729132     Document Type: Review

References (94)

1. Kohn EC, Jacobs W, Kim YS, Alessandro R, Stetler-Stevenson WG, Liotta LA: Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem 269:21505-21511, 1994
2. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: a review. Critical Rev Oral Biol Med 4:197-250, 1993
3. Stetler-Stevenson WG, Liotta LA, Kleiner DE, Jr: Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7:1434-1441, 1993
4. Freije JM, Diez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, Lopez-Otin C: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 269:16766-16773, 1994
5. Belaaouaj A, Shipley JM, Kobayashi DK, Zimonjic DB, Popescu N, Silverman GA, Shapiro SD: Human macrophage metalloelastase. Genomic organization, chromosomal location, gene linkage, and tissue-specific expression. J Biol Chem 270:14568-14575, 1995
6. Basset P, Wolf C, Rouyer N, Bellocq JP, Rio MC, Chambon P: Stromelysin-3 in stromal tissue as a control factor in breast cancer behavior. Cancer 74:1045-1049, 1994
7. Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, Basset P: Membrane-type matrix and metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92:2730-2734, 1995
8. Takino T, Sato H, Shinagawa A, Seiki M: Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library - MT-MMPs form a unique membrane-type sublcass in the MMP family. J Biol Chem 270:23013-23020, 1995
9. Fridman R, Toth M, Pena D, Mobashery S: Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 55:2548-2555, 1995
10. Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6:121-125, 1990
11. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-336, 1991
12. Ray JM, Stetler-Stevenson WG: Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 14:908-917, 1995
13. Tryggvason K, Hoyhtya M, Pyke C: Type IV collagenases in invasive tumors. Breast Cancer Res Treat 24:209-218, 1993
14. Cao J, Sato H, Takino T, Seiki M: The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem 270:801-805, 1995
15. Cross M, Dexter TM: Growth factors in development, transformation, and tumorigenesis. Cell 64:271-280, 1991
16. Dickson RB, Lippman ME: Molecular determinants of growth, angiogenesis and metastases in breast cancer. Semin Oncol 3:286-298, 1992
17. Blood CH, Zetter BR: Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1032:89-118, 1990
18. Folkman J: What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990
19. Fisher C, Gilbertson-Beadling S, Powers EA, Petzold G, Poor-man R, Mitchell MA: Interstitial collagenase is required for angiogenesis in vitro. Dev Biol 162:499-510, 1994
20. Folkman J, Klagsburn M: Angiogenic factors. Science 235: 442-447, 1987
21. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Eng J Med 324:1-8, 1990
22. Candle J, Bossy-Weasel E, Radvanyi F, Klagsburn M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66:1095-1104, 1991
23. Denekamp J, Hobson B: Endothelial-cell proliferation in experimental tumors. Br J Cancer 46:711-720, 1982
24. Hirst DG, Denekamp J, Hobson B: Proliferation kinetics of endothelial cells and tumor cells in three mouse mammary carcinomas. Cell Tissue Kinet 15:251-261, 1982
25. Wellstein A, Lippman ME: Fibroblast growth factors and breast cancer. In: Broder S (ed), Molecular Foundations of Oncology. Williams and Wilkins, Baltimore, 1991, p 403
26. Denekamp J: The current status of targeting tumor vasculature as a means of cancer therapy: an overview. Int J Radiat Biol 60:401-408, 1991
27. Maione ET, Sharpe RJ: Development of angiogenesis inhibitors for clinical applications. TIPS 11:457-461, 1990
28. Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M: Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 38:969-975, 1995
29. Hembry RM, Bagga MR, Reynolds JJ, Hamblen DL: Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 54:25-32, 1995
30. Manicourt DH, Fujimoto N, Obata K, Thonar EJ: Serum levels of collagenase, stromelysin-1, and TIMP-1. Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis. Arthritis Rheum 37:1774-17783, 1994
31. Okada Y, Naka K, Kawamura K, Matsumoto T, Nakanishi I, Fujimoto N, Sato H, Seiki M: Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: implications for bone resorption. Lab Invest 72:311-322, 1995
32. Koolwijk P, Miltenburg AM, van Erck MG, Oudshoorn M, Niedbala MJ, Breedveld FC, van Hinsbergh VW: Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation. J Rheumatol 22:385-393, 1995
33. Sepper R, Konttinen YT, Ding Y, Takagi M, Sorsa T: Human neutrophil collagenase (MMP-8), identified in bronchiectasis BAL fluid, correlates with severity of disease. Chest 107:1641-1647, 1995
34. Shapiro SD: Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. Am J Respir Crit Care Med 150:160-164, 1994
35. Bailey CJ, Hembry RM, Alexander A, Irving MH, Grant ME, Shuttleworth CA: Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intenstine. J. Clin Pathol 47:113-116, 1994
36. Takahara T, Furui K, Funaki J, Nakayama Y, Itoh H, Miyabayashi C, Sato H, Seiki M, Ooshima A, Watanabe A: Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 21:787-795, 1995
37. Milani S, Herbst H, Schuppan D, Grappone C, Pellegrini G, Pinzani M, Casini A, Calabro A, Ciancio G, Stefanini F: Differential expression of matrix metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 144:528-537, 1994
38. Newman KM, Malon AM, Shin RD, Scholes JV, Ramey WG, Tilson MD: Matrix metalloproteinases in abdominal aortic aneurysm: characterization, purification, and their possible sources. Connect Tissue Res 30:265-276, 1994
39. Irizarry E, Newman KM, Gandhi RH, Nackman GB, Halpern V, Wishner S, Scholes JV, Tilson MD: Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. J Surg Res 54:571-574, 1993
40. Wysocki AB, Staiano-Coico L, Grinnell F: Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 101:64-68, 1993
41. r 92,000 Type IV collagenase is increased in plasma of patients with colon and breast cancer. Cancer Res 53:140-146, 1993
42. Brown PD, Bloxidge RE, Stuart NSA, Gatter KC, Carmichael J: Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung carcinoma. J Natl Cancer Inst 85:574-578, 1993
43. Levy TD, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, Stetler-Stevenson WG: Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 51:439-444, 1991
44. Nuovo GJ, MacConnell PB, Simsir A, Valea F, French DL: Correlation of the in situ detection of polymerase chain reactionamplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 55:267-275, 1995
45. Zucker S, Lysik RM, Zarrabi HM, Moll U, Tickle SP, Stetler-Stevenson W, Baker TS, Docherty AJ: Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment. Ann N Y Acad Sci 732:248-262, 1994
46. Azzam HS, Arand G, Lippman ME, Thompson EW: Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 85:1758-1764, 1993
47. Zucker S, Lysik RM, Zarrabi MH, Stetler-Stevenson W, Liotta LA, Birkedal-Hansen H, Mann W, Furie M: Type IV collagenase/gelatinase (MMP-2) is not increased in plasma of patients with cancer. Cancer Epidemiol Biomarkers Prev 1:475-479, 1992
48. Wojtowicz-Praga S, Low J, Dickson R, Ness E, Barter J, McCann P, Hawkins MJ: Phase I study of batimastat (BB-94), a novel matrix metalloproteinase inhibitor in patients with advanced cancer. Invest New Drugs 14:193-202, 1996
49. 2-macroglobulin with proteinases. Biochem J 133:703-713, 1973
50. Sottrup JL, Birkedal HH: Human fibroblast collagenase-alpha-macroglobulin interactions: localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins. J Biol Chem 264:393-401, 1989
51. Grigioni WF, D'Errico A, Fortunato C, Fiorentino M, Mancini AM, Stetler-Stevenson WG, Sobel ME, Liotta LA, Onisto M, Garbisa S: Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod Pathol 7:220-225, 1994
52. Khokha R, Waterhouse P: The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction. J Neurooncol 18:123-127, 1993
53. Willenbrock F, Murphy G: Structure-function relationships in the tissue inhibitors of metalloproteinases. Am J Respir Crit Care Med 150:165-170, 1994
54. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM: Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 59:329-341, 1993
55. Reynolds JJ, Hembry RM, Meikle MC: Connective tissue degradation in health and periodontal disease and the roles of matrix metalloproteinases and their natural inhibitors. Adv Dent Res 8:312-319, 1994
56. Clark SD, Kobayashi DK, Welgus HG: Regulation of the expression of tissue inhibitor of metalloproteinases and collagenase by retinoids and glucocorticoids in human fibroblasts. J Clin Invest 80:1280-1288, 1987
57. Naylor MS, Stamp GW, Davies BD, Balkwill FR: Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 58:50-56, 1994
58. Polette M, Clavel C, Birembaut P, De Clerck YA: Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metallo-proteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. Pathol Res Pract 189:1052-1057, 1993
59. Takemura M, Azuma C, Kimura T, Kanai T, Saji F, Tanizawa O: Type-IV collagenase and tissue inhibitor of metalloproteinase in ovarian cancer tissues. Int J Gynaecol Obstet 46:303-309, 1994
60. Mohanam S, Wang SW, Rayford A, Yamamoto M, Sawaya R, Nakajima M, Liotta LA, Nicolson GL, Stetler-Stevenson WG, Rao JS: Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clin Exp Metastasis 13:57-62, 1995
61. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52:701-708, 1992
62. Johnson MD, Kim HR, Chesler L, Tsao-Wu G, Bouck N, Polverini PJ: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 160:194-202, 1994
63. Alvarez OA, Carmichael DF, DeClerck YA: Inhibition of collagenolytic activity and metastasis of tumour cells by a recombinant tissue inhibitor of metalloproteinases. J Natl Cancer Inst 82:589-595, 1990
64. Khokha R: Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the over-expression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 86:299-304, 1994
65. Naruo S, Kanayama H, Takigawa H, Kagawa S, Yamashita K, Hayakawa T: Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients. Int J Urol 1:228-231, 1994
66. Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J: Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer 70:506-512, 1994
67. Montgomery AM, Mueller BM, Reisfeld RA, Taylor SM, De Clerck YA: Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 54:5467-5473, 1994
68. Ray JM, Stetler-Stevenson WG: TIMP-2 expression modulates human melanoma cell adhesion and motility. Ann N Y Acad Sci 732:233-247, 1994
69. Visscher DW, Hoyhtya M, Ottosen SK, Liang CM, Sarkar FH, Crissman JD, Fridman R: Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 59:339-344, 1994
70. Wilde CG, Hawkins PR, Coleman RT, Levine WB, Delegeane AM, Okamoto PM, Ito LY, Scott RW, Seilhamer JJ: Cloning and characterization of human tissue inhibitor of metalloproteinases-3. DNA Cell Biol 13:711-718, 1994
71. Kishnani NS, Staskus PW, Yang TT, Masiarz FR, Hawkes SP: Identification and characterization of human tissue inhibitor of metalloproteina-3 and detection of three additional metalloproteinase inhibitor activities in extracellular matrix. Matrix Biol 14:479-488, 1995
72. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR: Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 269:9352-9360, 1994
73. Apte SS, Hayashi K, Seldin MF, Mattei MG, Hayashi M, Olsen BR: Gene encoding a novel murine tissue inhibitor of metalloproteinases (TIMP), TIMP-3, is expressed in developing mouse epithelia, cartilage, and muscle, and is located on mouse chromosome 10. Dev Dyn 200:177-197, 1994
74. Greenwald RA: Treatment of destructive arthritic disorders with MMP inhibitors. Potential role of tetracyclines. Ann N Y Acad Sci 732:181-198, 1994
75. Burns F, Stack MS, Gray MS, Patterson CA: Inhibition of purified collagenase from alkaline-burned rabbit corneas. Invest Ophtalmol Vis Sci 30:1569-1575, 1989
76. Karakiulakis G, Missirlis E, Maragoudakis ME: Basement membrane collagen-degrading activity from a malignant tumor is inhibited by anthracycline antibiotics. Biochim Biophys Acta 1035:218-222, 1990
77. Izquierdo-Martin M, Stein RL: Mechanistic studies on the inhibition of stromelysin by a peptide phosphonamidate. Bioorg Med Chem 1:19-26, 1993
78. Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M, McGeehan GM, Myers PL, Norton D, Salovich JM, Schoenen FJ, Ward P: Matrix metalloproteinase inhibitors containing a (carboxyalkyl) amino zinc ligand: modification of the P1 and P2′ residues. J Med Chem 37:674-688, 1994
79. Brown PD: Matrix metalloproteinase inhibitors: a new class of anticancer agents. Curr Opin Invest Drugs 2:617-626, 1993
80. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53:2087-2091, 1993
81. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54:4726-4728, 1994
82. Chirivi RGS, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciaro A, Brown PD, Giavazzi R: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58:460-464, 1994
83. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD: Inhibition of organ invasion by matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 55:3629-3633, 1995
84. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown PD, Giavazzi R: Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87:293-298, 1995
85. Wojtowicz S, Ness E, Dickson R, Low J, Barter J, McCann P, Hawkins M: Pharmacokinetics of batimastat (BB-94), a novel matrix metalloproteinase inhibitor in patients with advanced cancer. Proceedings of ASCO 14:474, 1995
86. Drummond AH, Beckett P, Bone EA, Brown PD, Davis M, Galloway WA, Taupin P, Wood LM, Davidson AH: BB-2516: An orally bioavailable matrix metalloproteinase inhibitor with efficacy in animal cancer models. Proceedings of AACR 36:100, 1995
87. Beckett RP, Davidson AH, Drummond AH, Huxley P, Whittaker M: Recent advances in matrix metalloproteinase inhibitor research. Drug Discovery Today 1:16-26, 1996
88. Hornung RL, Pearson JW, Beckwith M, Longo DL: Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor lines: In Vitro versus In Vivo activity. Cancer Res 52:101-107, 1992
89. Kraft AS, Baker VV, May WS: Bryostatin induces change in protein kinase C location and activity without altering cmyc gene expression in human promyelocytic (HL-60) cells. Oncogene 1:111-118, 1987
90. Kraft AS: Bryostatin-1: Will the oceans provide a cancer cure? J Natl Cancer Inst 85:1700-1792, 1993
91. Gopalakrishna R, Barsky SH: Tumor-promoter induced membrane bound protein kinase C regulates hematogenous metastasis. Proc Natl Acad Sci 85:612-616, 1988
92. Johnson MD, Torri JT, Lippman ME, Dickson RB: Regulation of the invasiveness of the human breast cancer line MCF-7 by agents that act through protein kinase-C. Submitted
93. Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NS, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F: Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 85:1812-1818, 1993
94. Prendville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M, Pettit GR: A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68:48-424, 1993